New-dol® 160 Suspension
Fever reliever analgesic
  • Paracetamol is a para-aminophenol derivative, non-opioid, and nonsalicylate.
  • Paracetamol has analgesic, antipyretic properties and weak anti-inflammatory activity. 
  • Paracetamol produces central and peripheral analgesia by elevation of the pain threshold and inhibition of prostaglandin biosynthesis; antipyretic action through action on the hypothalamic heat-regulating center, resulting in peripheral vasodilatation, increased blood flow through the  skin, sweating and heat loss.  
  • Paracetamol is readily absorbed orally and rectally, the initial rapid response occurs in less than half an hour and within 2 hours peak levels are achieved.

Each 5 ml of New-dol® 120 oral suspension contains:

  • Paracetamol                      120 mg

Each 5 ml of New-dol® 160 oral suspension contains:

  • Paracetamol                      160 mg

Each 5 ml of New-dol® 250 oral suspension contains:

  • Paracetamol                      250 mg

Each 1 ml of New-dol® Infant drops contains:

  • Paracetamol                  100 mg

New-dol® is indicated to relieve mild to moderate pain in many conditions as analgesic and antipyretic:

  • New-dol® is indicated for symptomatic relief of headache, sore throat, rheumatic aches and pains, influenza, feverishness and feverish colds.
  • In febrile conditions in children, teething, tonsillitis, measles aches and pain following vaccination or immunization.
  • New-dol® is often the analgesic or antipyretic of choice especially in patients in whom salicylates or other NSAIDs are contra-indicated; such patients include asthmatics or children in whom salicylates are contra-indicated because of the risk of Reye’s syndrome.

  New-dol® is contra-indicated in

  • Hypersensitivity to Paracetamol.
  • Chronic renal and/or hepatic diseases.
  • New-dol® absorption may be accelerated by drugs such as metoclopramide, and may be reduced if given within one hour of cholestyramine.
  • Probenecid can decrease paracetamol clearance and increase its plasma half life.
  • The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding. 
  • New-dol® has rare side effects at recommended dose. However, skin rash, other hypersensitivity reactions and hematological reactions occur occasionally.
  • Hepatotoxicity after large dose or prolonged treatment.


  • Infants (6–12 years): 5–10 ml of New-dol® 250, or 10 –15 ml of New-dol® 160
  • Children (1–5 years): 5–10 ml of New-dol® 120, or 5 –7.5 ml of New-dol® 160, or 5 ml of New-dol® 250
  • Infants (3–11 months): 2.5- 5 ml of New-dol® 120  or 2.5 ml of New-dol® 160 

Infant Drops:

  • Children (1–3 years): 1–2 ml. 
  • Infants (3–11 months): 1 ml.
  • Infants under 3 months: the usual dose is 10 mg/kg of body weight (reduced to 5 mg/kg of body weight if jaundiced).


  • Oral suspension and drops may be dosed every 4–6 hours if necessary.

Over dosage:

  • Immediate  medical managment is required in the events of overdose,even if symptoms of overdose aren’t present . 
  • paracetamol overdose may cause liver failure.
  • Early symptoms may cause pallor, nausea ,vomiting, diaphoresis and general malaise.
  • Overdose should be promptly treated by gastric lavage followed by IV N- acetylcystine or  methionine without waiting for the results of plasma paracetamol levels.
  • In all cases of suspected overdose, prompt medical attention is critical for adults , as well as for children, even if you don’t notice any signs or symptoms.
  • New-dol® should be given with care to patients with impaired kidney or liver functions and in patients taking other drugs which may affect the liver. 
  • New-dol® Suspension: Bottles of 60 ml. 
  • New-dol® Drops: Bottles of 15 ml with insert dropper.
  • Store in a dry place below 30 °C.